Actinium-225 offers a different approach by using alpha particles instead of beta particles. Alpha particles are highly energetic and travel only a short distance, which allows them to effectively ...

Actinium leads the industry in the application of the alpha-particle emitter actinium-225 (Ac-225), which is the most potent medical-grade radioisotope currently available.

Actinium announced ATNM-400, a novel, non-PSMA targeting, first in class radiotherapy for prostate cancer utilizing the Actinium-225 radioisotope. Initial preclinical data from ATNM-400 will be ...

Earnings Estimate Revisions for Actinium This cancer drug developer is expected to earn -$1.38 per share for the fiscal year ending December 2024, which represents a year-over-year change of 24.6%.

NEW YORK - Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM), a developer of targeted radiotherapies, announced the introduction of ATNM-400, a new radiotherapy for prostate cancer, and ...

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into an agreement for the supply of Actinium-225 (Ac-225) with Eckert & Ziegler. Under ...

Sandesh Seth, Actinium's Chairman and CEO, said, "The current era of radiotherapy is built on the clinical and commercial success of Pluvicto in prostate cancer. The field is now looking to ...

Sandesh Seth, Actinium's Chairman and CEO, said, "We are honored to have this opportunity to present Actinium Pharmaceuticals and highlight the significant progress we have made in the last ...

Actinium Pharmaceuticals, Inc., a pioneer in the development of targeted radiotherapies, announced it has entered into a sponsored research agreement with Memorial Sloan Kettering Cancer Center (MSKCC ...